Business Context and Reporting Period
Company: 22nd Century Group, Inc. (a holding company for 22nd Century Ltd, a plant biotechnology firm focused on modifying nicotinic alkaloids in tobacco).
Reporting Period: Quarterly period ended June 30, 2011 (Form 10-Q).
Key Event: On January 25, 2011, the Company completed a reverse merger with 22nd Century Limited, LLC and a concurrent private placement raising approximately $3.3 million in net cash proceeds. The financial statements reflect the operations of 22nd Century Ltd as the accounting acquirer.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2011 | Six Months Ended June 30, 2010 |
|---|---|---|
| Total Revenue | $415,806 | $1,800 |
| Net Loss | $(1,754,987) | $(690,117) |
| Net Loss Attributable to Common Shareholders | $(1,753,280) | $(690,113) |
| Loss Per Share (Basic & Diluted) | $(0.07) | $(0.08) |
| Cash Used in Operating Activities | $(2,290,312) | $(585,486) |
| Cash Provided by Financing Activities | $2,933,491 | $703,446 |
| Cash Balance (End of Period) | $86,575 | $33,236 |
| Total Assets | $2,755,529 | $2,800,520 |
| Total Liabilities | $5,482,666 | $4,889,192 |
| Shareholders' Deficit | $(2,727,137) | $(2,088,672) |
Liquidity: The Company reported negative working capital of approximately $0.5 million as of June 30, 2011, an improvement from negative working capital of $4.1 million at December 31, 2010, largely due to the private placement proceeds.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased significantly to $415,806 from $1,800 in the prior year period. This includes $272,266 in product revenue (primarily from a government research cigarette contract) and $143,540 in therapeutic grant credit income.
- Expense Increases: Operating expenses rose to $2,139,604 from $542,040.
- R&D: Increased to $797,055 (from $215,443), driven by $516,000 in Phase II-B clinical trial expenditures.
- G&A: Increased to $930,393 (from $244,665), largely due to $278,000 in stock-based compensation and increased professional fees.
- Sales & Marketing: New category with $230,704 in expenses related to product testing and branding.
- Debt Reduction: Current liabilities decreased from $4.8 million to $1.8 million. Approximately $614,000 of shareholder debt and accrued interest was converted to equity during the January 2011 private placement.
- Warrant Liability: A new warrant liability of $3,061,750 was recorded due to "down round" provisions in warrants issued during the private placement, classified as a derivative liability.
Outlook, Risks, and Management Commentary
- Capital Needs: Management expects to require additional capital in the fourth quarter of 2011 to fund Phase III clinical trials (estimated at $10 million), modified risk exposure studies (estimated at $2 million), and working capital. The Company plans to attempt to raise approximately $15 million.
- Regulatory Milestones: The Company does not expect FDA approval for its smoking cessation aid (X-22) until the fourth quarter of 2012 at the earliest. It expects to submit applications for modified risk tobacco products in 2012.
- Registration Rights Constraint: The Company cannot sell new equity securities until 90 days after the registration statement for the January 2011 private placement shares is declared effective (target date: December 4, 2011).
- Risk Factors:
- Liquidity Risk: The Company has a history of losses and negative working capital. Failure to raise capital could materially impact operations.
- Related Party Debt: The Company owes approximately $817,000 to North Carolina State University (NCSU) for patent costs and license fees, which are past due. While NCSU has deferred payment requests, failure to agree could lead to license termination.
- Going Concern: Management believes current funds will sustain operations into the fourth quarter of 2011, but no assurances are given.
Investor Verification Checklist
- Capital Raise Timeline: Verify the status of the registration statement for the January 2011 private placement shares and the ability to raise the projected $15 million in Q4 2011.
- NCSU Debt Status: Confirm the terms of the deferred payment arrangement with North Carolina State University and the risk of license termination if payments are not made.
- Warrant Liability Volatility: Monitor the fair value of the $3.06 million warrant liability, as changes in stock price and volatility will impact net income/loss.
- Grant Revenue Recognition: Verify the remaining $80,000 of deferred grant revenue and the timeline for its recognition upon completion of the Phase II-B trial.
- Inventory Valuation: Review the $916,159 inventory balance (mostly tobacco) for potential obsolescence or impairment given the limited commercial sales channels.